Aquestive Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Conference

Rhea-AI Summary

Aquestive Therapeutics (NASDAQ:AQST), a pharmaceutical company focused on innovative medicine delivery technologies, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The virtual event will take place from February 11-12, 2025.

The company's management team will conduct a fireside chat on February 11th at 3:20pm ET. Investors and interested parties can access the webcast through the 'Events and Presentations' section of Aquestive's investor relations website. A replay will remain available for 30 days after the event.

WARREN, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in the upcoming Oppenheimer 35^th Annual Healthcare Life Sciences Conference from February 11-12, virtually.

The Aquestive team will hold a fireside chat on February 11th at 3:20pm ET.

A webcast of the fireside chat will be available under the “Events and Presentations” page of the Investors section of the Company’s website. A replay of the webcast will be available for 30 days following the event. For more information, please visit investors.aquestive.com.

About Aquestive Therapeutics, Inc.
Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. We are developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. Aquestive has five commercialized products marketed by the Company and its licensees in the U.S. and around the world and is the exclusive manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm^®, and has proven drug development and commercialization capabilities. Aquestive is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. For more information, visit Aquestive.com and follow us on LinkedIn.

Forward Looking Statement
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements are based on the Company’s current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with the Company’s development work, including any delays or changes to the timing, cost and success of its product development activities and clinical trials and other risks and uncertainties affecting the Company described in the “Risk Factors” section and in other sections included in its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission. Given those uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by this cautionary statement. The Company assumes no obligation to update forward-looking statements or outlook or guidance after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by applicable law.

PharmFilm® and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc.

Investor Contact:
Brian Korb
astr partners
brian.korb@astrpartners.com

FAQ

When is Aquestive Therapeutics (AQST) presenting at the Oppenheimer Healthcare Conference 2025?

Aquestive Therapeutics will hold a fireside chat on February 11th, 2025, at 3:20pm ET during the Oppenheimer 35th Annual Healthcare Life Sciences Conference.

How can investors watch AQST's Oppenheimer Conference presentation?

Investors can watch the webcast through the 'Events and Presentations' page in the Investors section of Aquestive's website at investors.aquestive.com.

How long will AQST's Oppenheimer Conference presentation replay be available?

The webcast replay will be available for 30 days following the event on Aquestive's investor relations website.

Is the Oppenheimer Healthcare Conference 2025 where AQST is presenting in-person or virtual?

The Oppenheimer 35th Annual Healthcare Life Sciences Conference where Aquestive Therapeutics is presenting is being held virtually.